Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Syndax Pharma 35 GATEHOUSE DRIVE BUILDING D FLOOR 3 WALTHAM MA 02451 USA

P: 781-419-1400 F: 781-419-1420

Description:

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.

Key Statistics

Overview:

Market Capitalization, $K 537,455
Shares Outstanding, K 36,095
Annual Sales, $ 1,520 K
Annual Net Income, $ -56,050 K
Last Quarter Sales, $ 380 K
Last Quarter Net Income, $ -15,240 K
60-Month Beta 1.75
% of Insider Shareholders 9.50%
% of Institutional Shareholders 57.53%
Float, K 32,666
% Float 90.50%

Growth:

1-Year Return 67.92%
3-Year Return 36.61%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/06/20
Earnings Per Share ttm -1.88
EPS Growth vs. Prev Qtr -27.27%
EPS Growth vs. Prev Year -5.66%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

SNDX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -2.56
Price/Earnings to Growth N/A
Return-on-Equity % -132.06%
Return-on-Assets % -73.26%
Profit Margin % -3,687.50
Net Margin % N/A
Debt/Equity 0.38
Price/Sales 347.39
Price/Cash Flow N/A
Price/Book 8.25
Book Value/Share 1.77
Interest Coverage 0.00
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar